Home › Research › Drug development
Lecanemab (BAN2401): an anti-beta-amyloid monoclonal antibody for the treatment of Alzheimer disease
Vitek GE, Decourt B, Sabbagh MN.. Expert opinion on investigational drugs, 2023-02-28
Topic: Brain proteins, microglia and lab models
Plain-language summary
Introduction Nearly a dozen monoclonal antibodies (mAbs) directed against beta-amyloid (Aβ) have been developed for the treatment of Alzheimer disease (AD), and most of these mAbs are undergoing clinical trials. Newer mAbs have targeted more specific Aβ types. Lecanemab Eisai has a high affinity for large and soluble Aβ protofibrils.
What this study adds
Evidence grade: Low
This is a trial. This review describes lecanemab, an anti-beta-amyloid monoclonal antibody with high affinity for large soluble Aβ protofibrils, and notes that phase 2 data suggested a possible efficacy signal with manageable risk of amyloid-related imaging abnormalities. At the time of writing it was still being studied in phase 3 trials, so no cure or confirmed clinical benefit is established.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Vitek, G. E., Decourt, B., & Sabbagh, M. N. (2023). Lecanemab (BAN2401): an anti-beta-amyloid monoclonal antibody for the treatment of Alzheimer disease. Expert opinion on investigational drugs. https://doi.org/10.1080/13543784.2023.2178414
Vancouver
Vitek GE, Decourt B, Sabbagh MN. Lecanemab (BAN2401): an anti-beta-amyloid monoclonal antibody for the treatment of Alzheimer disease. Expert opinion on investigational drugs. 2023. doi:10.1080/13543784.2023.2178414. PMID: 36749830.
BibTeX
@article{vitek2023-36749830,
author = {Vitek, G. E. and Decourt, B. and Sabbagh, M. N.},
title = {{Lecanemab (BAN2401): an anti-beta-amyloid monoclonal antibody for the treatment of Alzheimer disease}},
journal = {Expert opinion on investigational drugs},
year = {2023},
doi = {10.1080/13543784.2023.2178414},
pmid = {36749830},
url = {https://doi.org/10.1080/13543784.2023.2178414}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Newer mAbs have targeted more specific Aβ types.
- Lecanemab Eisai has a high affinity for large and soluble Aβ protofibrils.
- Data from phase 2 clinical trials have suggested the possibility of a robust efficacy signal and manageable risk of amyloid-related imaging abnormalities (ARIAs).
- Lecanemab is currently being studied in phase 3 trials.
Why it matters
This review describes lecanemab, an anti-beta-amyloid monoclonal antibody with high affinity for large soluble Aβ protofibrils, and notes that phase 2 data suggested a possible efficacy signal with manageable risk of amyloid-related imaging abnormalities. At the time of writing it was still being studied in phase 3 trials, so no cure or confirmed clinical benefit is established.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designclinical trial
- Evidence strengthLow
How this study scored 47/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Expert opinion on investigational drugs) |
| Journal's citation record | 1 / 4 | Expert Opinion on Investigational Drugs: journal h-index 132 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | Design recorded as “clinical trial”, which our rubric does not rank (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 122 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 24.4 citations a year over 5 year(s) since 2023 |
| Impact for its field and year | 4 / 6 | Cited 17.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 6 other studies in this library |
| Still being cited | 3 / 4 | Cited 108 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Marwan Noel Sabbagh: h-index 65 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Creighton University: institution h-index 468 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 36749830) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 47 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1080/13543784.2023.2178414
- PubMed: 36749830
- Original source →
- Free full text: PubMed Central →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
6 studies in the alzhub library list this one in their references.
Related studies in Drug development from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.